Thus, specific priming can be desirable when it comes to the detection of very few BCR::ABL1 targets, e.g., in the case of TFR monitoring or therapy decisions regarding the participation of CML patients in TKI cessation studies, as suggested previously [13]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.